Table 4.
Effect of lifestyle modification, metformin or both on FGF21 and irisin in HIV-infected subjects
| No lifestyle modification-placebo (n = 11) | Lifestyle modification-placebo (n = 11) | No lifestyle modification-metformin (n = 13) | Lifestyle modification- metformin (n = 15) | P Value* | |
|---|---|---|---|---|---|
| FGF21 (pg/ml) | |||||
| Baseline | 109·9 [86·6, 171·5] | 114·7 [50·7, 362·0] | 96·6 [81·3,405·2] | 120·2 [63·1,169·2] | 0·99 |
| 12 months† | 171·3 [62·9,532·9] | 130·4 [80·3,672·8] | 169·9 [111·2,634·6] | 92·2 [67·6,165·6] | |
| % change at 12 months | 43 [4,124] | −30 [−39,25] | 29 [−21,57] | −10 [−24,16] | 0·08 |
| Irisin (μg/ml) | |||||
| Baseline | 2·09 [1·71,2·73] | 2·59 [2·01,3·13] | 1·91 [1·44,2·39] | 1·96 [1·55,2·36] | 0·04 |
| 12 months† | 2·37 [1·60,3·15] | 2·53 [1·97,2·92] | 1·98 [1·64,3·13] | 1·92 [1·56,2·08] | |
| % change at 12 months | 9 [−12,17] | 16 [−13,22] | −4 [−19,12] | −2 [−22,13] | 0·66 |
*
Non-normally distributed data are reported as median [interquartile range]; Overall P value by Kruskal–Wallis test.
†
Nine subjects randomized to no lifestyle modification-placebo, eight subjects randomized to lifestyle modification-placebo, 10 subjects randomized to no lifestyle modification-metformin, and nine subjects randomized to lifestyle modification-metformin completed the interventional study at 12 months.